Pregnancy
Although there are no full controlled studies of d4T (stavudine, Zerit) in pregnancy, a recent study has reported that d4T in conjunction with other antiretrovirals was well tolerated in ten pregnant women[1]. However, because of the small size of this study, and the potential low risk of blood disorders, congenital abnormalities and miscarriage, d4T should be administered to pregnant women with caution[2][3].
Pregnant women taking ddI and d4T together may be at increased risk of the life-threatening condition lactic acidosis. This was the subject of a warning by the United States Food and Drug Administration and Bristol-Myers Squibb, d4T’s manufacturer, in January 2001, following three reported deaths in pregnant women taking these two drugs.
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research